DMRA compared with CBIO: revenue, margins and what each company keeps, and the suppliers and customers both name

DMRADamora Therapeutics, Inc.

Mkt capRevenueRevenue

CBIOCrescent Biopharma, Inc.

Mkt capRevenueRevenue

Compare

DMRADamora Therapeutics, Inc.

CBIOCrescent Biopharma, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only DMRA 3

—Paragonunlistedsupplier

—Pre-Acquisition Damoraunlistedsupplier

—Bridge Medicinesunlistedsupplier

Shared 0

No shared counterparties.

Only CBIO 5

CRLCharles River Laboratoriessupplier

—Paragon Therapeuticsunlistedsupplier

—WuXi Biologics (Hong Kong)unlistedsupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

—

WuXi Biologics Ireland

unlistedsupplier

1 more · CBIO chain ›

DMRADamora Therapeutics, Inc.

21.55▼−1.40%

Mkt cap$1.4BRevenue—

CBIOCrescent Biopharma, Inc.

12.75▼−1.47%

Regular sessionNov 6 '26

Mkt cap$480.6MRevenue$1MQ1 FY26

Compare

Regular sessionNov 6 '26

DMRADamora Therapeutics, Inc.

CBIOCrescent Biopharma, Inc.

21.55▼−1.40%

Price

12.75▼−1.47%

$1.4B

Mkt cap

$480.6M

—

Revenue

$1MQ1 FY26

DMRA21.55▼−1.40%vsCBIO12.75▼−1.47%Regular sessionNov 6 '26